Trevi Therapeutics annual free cash flow
2018
2019
2020
2022
2023
2024
2025
Trevi Therapeutics Free Cash Flow (FCF) History (TRVI)
Trevi Therapeutics reported −$42.1M in free cash flow for fiscal 2025, a decrease of $3.8M from the previous fiscal year.
View full Trevi Therapeutics company overviewTrevi Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$42.1M | −$3.8M | — | — |
| 2024 | 2024-12-31 | −$38.3M | −$6.4M | — | — |
| 2023 | 2023-12-31 | −$31.8M | −$3.5M | — | — |
| 2022 | 2022-12-31 | −$28.3M | $698,000 | — | — |
| 2020 | 2020-12-31 | −$29.0M | −$5.9M | — | — |
| 2019 | 2019-12-31 | −$23.1M | −$4.7M | — | — |
| 2018 | 2018-12-31 | −$18.4M | — | — | — |
Trevi Therapeutics quarterly free cash flow
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q3.20
Q1.23
Q2.23
Q3.23
Q4.23
Q3.24
Q3.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$17.6M | −$11.2M | — | — |
| Q1 2026 | 2026-03-31 | −$16.8M | −$9.5M | — | — |
| Q3 2025 | 2025-09-30 | −$10.9M | −$977,000 | — | — |
| Q3 2024 | 2024-09-30 | −$9.6M | −$1.3M | — | — |
| Q4 2023 | 2023-12-31 | −$6.4M | $601,000 | — | — |
| Q3 2023 | 2023-09-30 | −$7.3M | −$1.1M | — | — |
| Q2 2023 | 2023-06-30 | −$9.9M | −$2.2M | — | — |
| Q1 2023 | 2023-03-31 | −$8.3M | −$3.2M | — | — |
| Q3 2020 | 2020-09-30 | −$7.0M | −$2.9M | — | — |
| Q4 2019 | 2019-12-31 | −$6.2M | −$1.4M | — | — |
| Q3 2019 | 2019-09-30 | −$7.7M | −$3.7M | — | — |
| Q2 2019 | 2019-06-30 | −$5.1M | $559,000 | — | — |
| Q1 2019 | 2019-03-31 | −$4.1M | −$94,000 | — | — |
| Q4 2018 | 2018-12-31 | −$4.8M | — | — | — |
| Q3 2018 | 2018-09-30 | −$4.0M | — | — | — |
| Q2 2018 | 2018-06-30 | −$5.6M | — | — | — |
| Q1 2018 | 2018-03-31 | −$4.0M | — | — | — |
Trevi Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$23.1M to −$42.1M, a net decrease of $19.0M. Trevi Therapeutics's latest reported quarter, Q2 2026, generated −$17.6M in free cash flow, a decrease of $11.2M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Trevi Therapeutics filings at SEC.gov ↗